Latest News in Cancer
Stay updated with the most recent articles and resources.
Main Topics
CARSgen presents latest data of Satri-cel therapy in ASCO 2024
At ASCO 2024, CARSgen unveiled new data on Satri-cel, their promising CAR-T cell therapy for cancer treatment. The latest findings highlighted significant advancements in efficacy...
Can CAR T cell therapy shortcomings be avoided by NK Cell therapy?
NK Cell therapy vs CAR T-Cell therapy The FDA’s approval of the first CAR T cell therapy in 2017 was widely celebrated as a significant...
CAR T Cell therapy for refractory systemic lupus erythematosus in China
CAR T cell therapy has emerged as a promising treatment for refractory systemic lupus erythematosus (SLE) in China. This innovative approach involves genetically modifying a...
Zevorcabtagene autoleucel (Zevra-cel therapy) approved for R/R multiple myeloma
SHANGHAI, China, April 30, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic...
After amazing growth of CAR T-Cell therapy: what’s next?
CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient's T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in...
Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant...
Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
"Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while...
Alectinib has been approved by the USFDA as adjuvant treatment for ALK-positive non-small cell lung cancer
The FDA's recent approval of alectinib marks a significant advancement in the treatment landscape for ALK-positive non-small cell lung cancer (NSCLC). As an adjuvant therapy,...
NMPA approves zevorcabtagene autoleucel CAR T Cell therapy for R/R multiple myeloma
Zevor-Cel therapy Chinese regulators have approved zevorcabtagene autoleucel (zevor-cel; CT053), an autologous CAR T-cell therapy, for the treatment of adult patients with multiple myeloma that...
Understanding BCMA: A Revolutionary Target in Cancer Treatment
Introduction In the ever-evolving realm of oncological treatment, scientists persistently seek out unconventional targets that can amplify the effectiveness of interventions while mitigating unwanted repercussions....
Human-Based CAR T Cell Therapy: Breakthroughs and Challenges
Human-based CAR T-cell therapy revolutionizes cancer treatment by genetically modifying a patient's own immune cells to target and destroy cancer cells. By harnessing the power...
Understanding Cytokine Release Syndrome: Causes, Symptoms, and Treatment
Cytokine Release Syndrome (CRS) is an immune system reaction often triggered by certain treatments like immunotherapy or CAR-T cell therapy. It involves an excessive release...
Need help? Our team is ready to assist you.
We wish a speedy recovery for your loved ones.